Receptor specific atrial natriuretic peptides
    10.
    发明授权
    Receptor specific atrial natriuretic peptides 有权
    受体特异性心房利钠肽

    公开(公告)号:US06525022B1

    公开(公告)日:2003-02-25

    申请号:US09154390

    申请日:1998-09-16

    IPC分类号: A61K3812

    CPC分类号: C07K14/58 A61K38/00

    摘要: Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.

    摘要翻译: 含有各种取代,特别是G16R的人受体选择性心房利钠因子变体对人A受体显示相同的效力和结合亲和力,但对人清除或C-受体的亲和力降低。 这些ANF变体具有利钠,利尿和血管舒张活性,但具有增加的代谢稳定性,使其适合于治疗充血性心力衰竭,急性肾衰竭和肾性高血压。